Format

Send to

Choose Destination
Clin Colorectal Cancer. 2016 Dec;15(4):292-297. doi: 10.1016/j.clcc.2016.06.003. Epub 2016 Jun 23.

TAS-102 (Lonsurf) for the Treatment of Metastatic Colorectal Cancer. A Concise Review.

Author information

1
Medical Oncology Department, Fondazione Poliambulanza, Brescia, Italy. Electronic address: zanib@numerica.it.
2
Medical Oncology Department, Fondazione Poliambulanza, Brescia, Italy.
3
Medical Oncology Department, Ospedale di Treviglio, Italy.

Abstract

Within the past several years, no chemotherapy has been sufficient to increase the overall survival of patients with chemorefractory colorectal cancer. TAS-102 (Lonsurf) is an oral fluoropyrimidine that is formed by the combination of 2 active drugs: trifluridine (a nucleoside analog) and tipiracil hydrochloride (a thymidine phosphorylase inhibitor). This drug extended the median overall survival by approximately 2 months compared with placebo in a randomized phase III trial composed of Asian and non-Asian patients with refractory (or intolerant) metastatic colorectal cancer. The clinical development of TAS-102 began approximately a decade ago and included 2 pivotal randomized studies, which are discussed in this review. This drug has just been approved in Japan, and as soon as possible, it will be marketed in Western countries as well; it will therefore become the standard of care for this patient population. The optimal combination of TAS-102 with other agents, as well as the mechanism of resistance to this regimen should be defined in the near future.

KEYWORDS:

Chemotherapy; Overall survival; Phase III trial; Pretreated patients; Trifluoridine/tipiracil

PMID:
27431756
DOI:
10.1016/j.clcc.2016.06.003
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center